CD19 and leukemia: The anti-CD19-CAR T-cell therapy derived from donor T cells was a selection of salvage therapy to B-ALL patients who relapsed after allo-HSCT, because allogeneic anti-CD19-CAR T-cells exerted a graft versus leukemia(GVL) effect (11, 26–28).